Current Headlines

  1. Crown Bioscience Strengthens Immuno-Oncology Capabilities With HuGEMM
    4/5/2016

    Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554), a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, is pleased to announce that it has developed and validated a unique set of models for immuno-oncology called HuGEMM™.

  2. Zenith Technologies And GE Healthcare Strike Biopharma Alliance
    4/4/2016

    Zenith Technologies and GE Healthcare’s Life Sciences business have announced a collaboration to support biopharmaceutical manufacturing deployment.

  3. SELLAS To Present Phase 2 Results For WT1 Cancer Vaccine At ASCO
    4/1/2016

    SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat cancers and central nervous system (CNS) diseases, today announced that results from a Phase 2 trial of the Company's WT1 cancer vaccine in patients with AML have been selected for an oral presentation during the Annual Meeting of the American Society of Clinical Oncology (ASCO), being held in Chicago, IL, June 3-7, 2016.

  4. Aplidin Shows Positive Results In Phase III Multiple Myeloma Trial
    3/31/2016

    PharmaMar (MSE:PHM) today announced positive top-line results of its Phase III clinical trial -ADMYRE- with Aplidin® (plitidepsin) in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM).

  5. Janssen Discontinues Fulranumab Phase 3 Development Program
    3/31/2016

    Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that it is discontinuing the Phase 3 development program for fulranumab in osteoarthritis pain.

  6. BioLineRx Reports Successful Results In Phase 2 Trial For AML
    3/30/2016

    BioLineRx (NASDAQ/TASE: BLRX) announced today positive top-line results from BL-8040's Phase 2 clinical trial in relapsed or refractory acute myeloid leukemia (r/r AML). Detailed results are planned to be presented at an upcoming scientific conference.

  7. Immunocore's IMCgp100 Starts Phase I Trial For Uveal Melanoma
    3/30/2016

    Immunocore, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune disease, today announced that it has recruited the first patient into a Phase I monotherapy trial of its lead programme, IMCgp100, for the treatment of uveal melanoma.

  8. Evelo Biosciences Establishes Scientific Advisory Board
    3/29/2016

    Evelo Biosciences, the pioneer of Oncobiotic™ Therapies, microbiome-based therapeutics for cancer, today announced the establishment of its Scientific Advisory Board (SAB). The newly appointed SAB will serve as a strategic resource for Evelo as the company advances the development of its therapeutic platform.

  9. Bluegrass Vascular Technologies Announces First Clinical Use Of Catheter System
    3/29/2016

    Bluegrass Vascular Technologies, Inc. (BVT), a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today that its Surfacer® Inside-Out® Access Catheter System was successfully used on a patient facing life-threatening complications from end-stage renal disease.

  10. Forge Therapeutics And Active Motif To Partner On Epigenetic R&D
    3/28/2016

    Forge Therapeutics, Inc., a biotechnology company discovering innovative therapeutics using a breakthrough drug discovery platform targeting metalloproteins, and Active Motif, a leader in developing tools to enable epigenetics research, announced recently a research collaboration aimed at advancing epigenetic research related to the family of iron-containing lysine demethylases known as Jumonji KDMs.